Introduction
============

Oral squamous cell carcinoma (OSCC) is a highly aggressive neoplasm found in the oral and maxillofacial region, with approximately 354,864 new cases and 177,384 deaths in 2018, worldwide ([@b1-ol-0-0-11822]). The most significant risk factors are smoking and alcohol consumption ([@b2-ol-0-0-11822],[@b3-ol-0-0-11822]). Despite recent advances in cancer treatment, such as surgery, radiotherapy or chemotherapy, the overall five-year survival rate for OSCC remains less than 50% ([@b4-ol-0-0-11822]). Therefore, novel therapeutic methods are required to treat this disease. Recently, advances in cancer immunotherapy have made considerable progress. Immunotherapy can be used to manipulate the development of early carcinogenesis, improve the quality of life and extend the patient survival time by improving the antitumor immune functions of the patients ([@b5-ol-0-0-11822]). Therefore, immunotherapy may be considered an alternative treatment strategy for OSCC.

Interleukin-21 (IL-21) is a member of the γ chain cytokine family, which is mainly produced by activated CD4^+^ T cells and natural killer (NK) cells ([@b6-ol-0-0-11822]). IL-21 can regulate the innate and adaptive immune response, which have been found to serve a diverse range of important roles in inflammation and tumor progression ([@b7-ol-0-0-11822]). For example, IL-21 can critically regulate B cell function and amplify NK cell function, and can also regulate potent antitumor activity and facilitate heightened tumor-specific T lymphocyte function ([@b8-ol-0-0-11822]). Moreover, IL-21 was revealed to stimulate the expansion of CD8^+^ T cells and increase their cytotoxicity, which in turn promoted the proliferation and antibody production of T cell-dependent B cells; this induced the differentiation and activation of NK cells, and reduced the number of Treg cells in tumors ([@b8-ol-0-0-11822],[@b9-ol-0-0-11822]). Previously, the application of recombinant human IL-21 to patients or animals has demonstrated significant antitumor activity in both nonclinical and clinical studies ([@b10-ol-0-0-11822]--[@b12-ol-0-0-11822]). Phase I and II clinical trials of IL-21 have been conducted in patients with renal cell carcinoma, non-Hodgkin\'s lymphoma and malignant melanoma ([@b10-ol-0-0-11822]--[@b12-ol-0-0-11822]); the results indicated that the therapeutic administration of IL-21 had a high validity and safety profile in patients ([@b13-ol-0-0-11822]--[@b15-ol-0-0-11822]).

Thus, the present study aimed to investigate the expression levels of IL-21 in OSCC tissues and the antitumor effects of IL-21 in CAL-27 cells *in vitro*. Moreover, the role of IL-21 in OSCC immunotherapy was further determined.

Materials and methods
=====================

### Human OSCC samples

Ethical approval was obtained from the Ethics Committee of the Yantai Yuhuangding Hospital and informed written consent was provided from all patients. None of the patients with OSCC had received any chemotherapy or radiotherapy before excision. OSCC and adjacent normal tissues (positioned \>5 cm away from the tumor) were obtained from 45 patients with OSCC (29 men and 16 women; age range, 42--79 years; mean age, 59 years) who underwent surgical resection at the Yantai Yuhuangding Hospital between October 2016 and April 2018. All samples were confirmed by pathological examination. The histological grade and tumor stage were assigned according to the World Health Organization (WHO) ([@b16-ol-0-0-11822]) and the International Union Against Cancer classification system ([@b17-ol-0-0-11822]).

### Reagents

DMEM (cat. no. 11960--044), FBS (cat. no. 12484-010), penicillin-streptomycin (cat. no. 15140-122), TRIzol^®^ reagent (cat. no. 15596-026), rabbit anti-IL-21 polyclonal antibody (cat. no. PA5-34801; 1:1,000), mouse anti-β-actin monoclonal antibody (cat. no. MA1-744; 1:5,000), horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG antibody (cat. no. 31430; 1:3,000) and HRP-conjugated goat anti-rabbit IgG antibody (cat. no. 31460; 1:3,000) were all obtained from Invitrogen; Thermo Fisher Scientific, Inc. The rabbit anti-cleaved (c)-caspase-3 antibody (cat. no. ab2302; 1:2,000), rabbit anti-Bax antibody (cat. no. ab32503; 1:2,000), rabbit anti-Bcl-2 antibody (cat. no. ab32124; 1:1,000), rabbit anti-JNK1+JNK2+JNK3 antibody (cat. no. ab179461; 1:2,000), rabbit anti-JNK1+JNK2+JNK3 (phospho T183+T183+T221; 1:1,000) antibody (cat. no. ab124956), rabbit anti-AKT1+AKT2+AKT3 antibody (cat. no. ab185633; 1:1,000) and rabbit anti-AKT3 (phospho S472)+AKT2 (phospho S474)+AKT1 (phospho S473) antibody (cat. no. ab192623; 1:2,000) were obtained from Abcam. The RevertAid First Strand cDNA Synthesis kit (cat. no. K1622), SuperSignal™ West Pico PLUS Chemiluminescent substrate (cat. no. 34580) and the SYBR™ Green PCR Master mix (cat. no. 4334973) were purchased from Thermo Fisher Scientific, Inc. The Cell Counting Kit-8 (CCK-8; cat. no. E606335) and the TUNEL apoptosis assay kits (cat. no. E607172) were purchased from Sangon Biotech Co., Ltd. Finally, the Annexin V-allophycocyanin (APC)/7′-aminoactinomycin D (AAD) Apoptosis Assay kit (cat. no. KGA1026) was obtained from Nanjing KeyGen Biotech Co., Ltd.

### Cell culture and reagents

The human tongue squamous cell carcinoma cell line CAL-27 was obtained from the Central Laboratory of Yantai Yuhuangding Hospital of Qingdao University (Yantai, China). The cells were cultured in DMEM, supplemented with 10% FBS and 100 U/ml penicillin-streptomycin, and maintained in a humidified atmosphere at 37°C with 5% CO~2~.

### Adenovirus infection

The adenovirus vector (pAd-Track) was supplied by Dr Wang Shengzhi of Yantai Yuhuangding Hospital (Yantai, China) and the recombinant adenovirus expressing human IL-21 (Ad-IL-21) was constructed by Shanghai Shenggong Biology Engineering Technology Service, Ltd. Ad-IL-21 or Ad-null (pAd-Track null vector) were cloned into the adenovirus vector. When CAL-27 cells number reached 1×10^6^, cells were infected with 1×10^8^ µg Ad-null or Ad-IL-21 by polybrene (Sigma) and the control cells were treated with PBS for 24 h at 37°C.

### Immunohistochemical (IHC) analysis

The expression levels of IL-21 were analyzed by IHC using standard staining procedures. Briefly, antigen retrieval was performed by incubating the sections in 10 mM citric acid buffer (pH 6.0) at 100°C for 15 min. Subsequently, sections were dewaxed in xylene I and II at room temperature, for 20 min each, and rehydrated in a descending ethanol series (absolute ethanol for 5 min, 95% ethanol for 5 min, 90% ethanol for 5 min and 80% ethanol for 5 min). Following three washes with PBS-Tween (0.05% Tween-20 in PBS), the sections were incubated in 5% BSA (Sangon Biotech Co., Ltd.) for 45 min at room temperature. The sections were subsequently incubated at 4°C overnight with rabbit anti-IL-21 polyclonal antibody diluted in 1X PBST (1:100). Following the primary antibody incubation, the membranes were washed in PBST and incubated with a HRP-conjugated goat anti-rabbit IgG secondary antibody (1:100) at room temperature for 45 min. The slides were subsequently stained with 3,3′-diaminobenzidine tetrahydrochloride at room temperature for 10 min. Finally, the sections were rehydrated with ethanol (80% ethanol for 5 min, 90% ethanol for 5 min, 95% ethanol for 5 min and absolute ethanol for 5 min), cleared and mounted with neutral tree gum, and counterstained with 0.5% Harris\' hematoxylin at room temperature for 5 min. The images were screened using a confocal microscope (magnification, ×100 and ×400).

### Western blotting

Total protein were extracted from cells or tissues using TNE lysis buffer \[1.0% (vol/vol) Triton X-100, 10 mM Tris-HCl, pH 7.5, 120 mM NaCl, 25 mM KCl, 1 lg/ml leupeptin, 1 lg/ml pepstatin, 2 lg/ml aprotinin, and 0.5 mM phenylmethylsulfonyl fluoride\] ([@b18-ol-0-0-11822]). Total protein was quantified using the BCA method ([@b19-ol-0-0-11822]) and 30 µg protein/lane was separated via SDS-PAGE on a 10% gel. The separated proteins were subsequently transferred onto PVDF membranes (Bio-Rad Laboratories, Inc.) and blocked in 10% non-fat milk in TBS-Tween (0.05% Tween-20) at room temperature for 2 h. The membranes were incubated with primary antibodies against: Polyclonal IL-21 (1:1,000); caspase-3 (1:2,000); Bax (1:2,000); Bcl-2 (1:1,000); JNK1+JNK2+JNK3 (1:2,000); JNK1+JNK2+JNK3 (phospho T183+T183+T221; 1:1,000); rabbit anti-AKT1+AKT2+AKT3 (1:1,000); AKT3 (phospho S472)+AKT2 (phospho S474)+AKT1 (phospho S473; 1:2,000) and monoclonal β-actin (1:5,000) overnight at 4°C. Following the primary antibody incubation, the membranes were incubated with HRP-conjugated goat anti-mouse IgG (1:3,000) and HRP-conjugated goat anti-rabbit IgG secondary antibodies (1:3,000) at room temperature for 1 h. Protein bands were assessed using chemiluminescence substrates, which is an enhanced chemiluminescent HRP substrate that enables picogram to high femtogram-level protein detection (SuperSignal™ West Pico PLUS Chemiluminescent substrate; Thermo Fisher Scientific, Inc.) and the expression levels were quantified using Image-Pro Plus software (version 6.0; Media Cybernetics, Inc.).

### Reverse transcription-quantitative PCR (RT-qPCR)

Total RNA was extracted from cells using TRIzol^®^ reagent (Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. Total RNA was reverse transcribed into cDNA using the RevertAid First Strand cDNA Synthesis kit (Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocol. RT was performed as follows: 55°C for 30 min, followed by 95°C for 5 min and 5°C for 5 min. qPCR was subsequently performed using the SYBR™ Green PCR Master mix and a LightCycler^®^ 480 system (Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocols. The following primer sequences were used for qPCR: IL-21 forward, 5′-ATCCAGTCCTGGCAACATGG-3′ and reverse, 5′-TGTGGCGATCTTGACCTTGG-3′; and β-actin forward, 5′-CCACTGGCATCGTGATGGAC-3′ and reverse, 5′-ACGGATGTCCACGTCACACT-3′. The following thermocycling conditions were used for qPCR: 95°C for 3 min; 40 cycles of 95°C for 30 sec, 60°C for 30 sec, 72°C for 45 sec; and a final extension at 72°C for 1 min. Expression levels were quantified using the 2^−ΔΔCq^ method ([@b20-ol-0-0-11822]) and normalized to β-actin.

### Cell viability assay

The infected CAL-27 cells were plated into 96-well plates at a density of 5×10^4^ and cultured for 48 h. Cell viability was measured using the CCK-8 assay kit (Sangon Biotech Co., Ltd.), according to the manufacturer\'s protocol. Briefly, the cells were washed with DMEM and incubated with 10 µl CCK-8 solution at 37°C for 4 h. Subsequently, the absorbance was measured at 450 nm with a spectrophotometer (BioTek Instruments, Inc.).

### Cell migration assay

The infected CAL-27 cells were plated into 10 cm dish at a density 5×10^6^ and cultured for 24 h. Subsequently, the cells were scraped with a 200-µl pipette tip and washed with PBS three times, prior to being cultured in DMEM without FBS. The images of the scratch wounds were captured at 0 or 24 h using a confocal microscope (magnification, ×400). The width of each wound was quantified using Image-Pro Plus 6.0 software (Media Cybernetics, Inc.). The cell migration rate (%) was calculated as follows: \[(Width of wound at 0 h-width of wound at 24 h)/width of wound at 0 h\] ×100%.

### TUNEL staining

The infected CAL-27 cells were plated into 6-well plates dish at a density 2×10^5^ and cultured for 48 h. The TUNEL assay was performed using a TUNEL apoptosis assay kit, according to the manufacturer\'s protocol. Briefly, the cells were fixed in 4% paraformaldehyde at room temperature for 30 min, permeabilized in 0.5% Triton X-100 on ice for 2 min and incubated with a dUTP and TDT enzyme reaction mixture in a humidified atmosphere at 37°C for 60 min. Subsequently, the slides were incubated with streptavidin-fluorescein at 37°C for 30 min and counterstained with 5 µg/ml DAPI at room temperature for 5 min. The slices were mounted with neutral tree gum. TUNEL-positive cells were observed in ≥5 randomly selected fields of view using a fluorescent microscope (Bio-Rad Laboratories, Inc.; magnification, ×400). The positive cells generated a bright green fluorescence.

### Flow cytometric analysis of apoptosis

Briefly, the infected cells (5×10^5^ cells/well) were harvested with 0.25% trypsinization and centrifugated at 300 × g for 5 min at room temperature, then rinsed twice with PBS and resuspended in 500 µl binding buffer solution at a density of 1×10^5^ cells/ml. The cells were subsequently stained with 5 µl Annexin V-APC and 5 µl 7-AAD using the Annexin V-APC/AAD Apoptosis Assay kit at room temperature for 15 min in the dark, according to the manufacturer\'s protocol. Apoptotic cells were analyzed using a CytoFLEX flow cytometer and CytExpert software (version 2.0; Beckman Coulter, Inc.) within 1 h.

### Statistical analysis

Statistical analysis was performed using SPSS 19.0 software (IBM Corp.). Data are presented as the mean ± standard deviation, and all experiments were performed in triplicate. Statistical differences between the groups were analyzed with the paired Student\'s t-test or a one-way ANOVA, followed by a Tukey\'s post hoc test for multiple comparisons. A χ^2^ test was used to determine the association between the expression levels of IL-21 and OSCC clinical and histopathological features. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### IL-21 expression levels are decreased in OSCC tissues

The expression levels of IL-21 in OSCC and adjacent normal tissues were analyzed using RT-qPCR and western blotting. The results indicated that both the mRNA and protein expression levels of IL-21 were significantly decreased in OSCC tissues compared with the adjacent normal tissues ([Fig. 1A-C](#f1-ol-0-0-11822){ref-type="fig"}). Furthermore, IHC analysis was performed to analyze IL-21 expression levels; the positive rate of IL-21 detection was 20% (9/45) in OSCC tissues and 62% (28/45) in the adjacent tissues ([Fig. 1D](#f1-ol-0-0-11822){ref-type="fig"}). The positive rate of IL-21 detection decreased in the OSCC tumor tissue compared with the adjacent normal tissues ([Fig. 1D](#f1-ol-0-0-11822){ref-type="fig"}). The associations between the expression levels of IL-21 and the clinicopathological features of OSCC are presented in [Table I](#tI-ol-0-0-11822){ref-type="table"}. IL-21-negative tumors were significantly associated with the TNM status, pathological grade and lymphocytic infiltration ([Table I](#tI-ol-0-0-11822){ref-type="table"}). Overall, these findings indicated that IL-21 expression levels may be decreased in OSCC tissues, which may be positively associated with the malignant progression of OSCC.

### IL-21 inhibits the proliferation and migration of OSCC cells in vitro

To verify the roles of IL-21 in OSCC, a recombinant Ad was constructed to overexpress IL-21 (Ad-IL-21), which was used to infect CAL-27 cells *in vitro*. Initially, the expression levels of IL-21 mRNA and protein were analyzed using RT-qPCR ([Fig. 2A](#f2-ol-0-0-11822){ref-type="fig"}) and western blotting respectively ([Fig. 2B and C](#f2-ol-0-0-11822){ref-type="fig"}) to demonstrate the proof of successful infection. The results demonstrated that Ad-IL-21 infection significantly increased the mRNA and protein expression levels of IL-21 compared with the control and Ad-null cells ([Fig. 2A-C](#f2-ol-0-0-11822){ref-type="fig"}). Subsequently, cell proliferation was analyzed using the CCK-8 method. The Ad-IL-21 group exhibited a significant decrease in cell viability compared with the control or the Ad-null group ([Fig. 3A](#f3-ol-0-0-11822){ref-type="fig"}). Thus, it was suggested that IL-21 overexpression may inhibit the proliferation of CAL-27 cells. Furthermore, the role of IL-21 in cell migration was confirmed using a wound-healing assay. The results revealed that the cell migratory activity of the Ad-IL-21 group was significantly decreased at 24 h compared with the control or the Ad-null groups ([Fig. 3B and C](#f3-ol-0-0-11822){ref-type="fig"}). Therefore, these results revealed that IL-21 overexpression may inhibit the proliferation and migration of CAL-27 cells *in vitro*.

### IL-21 induces the apoptosis of OSCC cells in vitro

TUNEL staining was performed to determine the role of IL-21 in cell apoptosis. The number of apoptotic cells was significantly increased in the Ad-IL-21 group compared with the control or Ad-null groups ([Fig. 4A and B](#f4-ol-0-0-11822){ref-type="fig"}). In addition, the expression levels of the pro-apoptotic proteins, c-caspase-3 and Bax, and the anti-apoptotic protein Bcl-2, were investigated. Western blotting indicated that the overexpression of IL-21 could significantly increase the expression levels of c-caspase-3 and Bax, while decrease the expression levels of Bcl-2, and also significantly increase the Bax/Bcl-2 ratio compared with the control and Ad-null groups ([Fig. 4C and D](#f4-ol-0-0-11822){ref-type="fig"}). Apoptosis was also investigated using flow cytometric analysis ([Fig. 5](#f5-ol-0-0-11822){ref-type="fig"}); the number of apoptotic cells in the Ad-IL-21 group was significantly increased compared with the control or Ad-null groups. These results suggested that IL-21 may promote the apoptosis of CAL-27 cells *in vitro*.

### IL-21 inhibits the activation of the JNK signaling pathway

To determine the molecular mechanism of IL-21 in CAL-27 cells, the activation of JNK and AKT was analyzed using western blotting. The results indicated that IL-21 overexpression significantly decreased the phosphorylation levels of JNK compared with the control and Ad-null groups ([Fig. 6A and B](#f6-ol-0-0-11822){ref-type="fig"}), but had no effect on the phosphorylation levels of AKT ([Fig. 6C and D](#f6-ol-0-0-11822){ref-type="fig"}). Therefore, the inhibitory effect of IL-21 in CAL-27 cells may function through the JNK signaling pathway.

Discussion
==========

The CD4^+^ T-cell population is the main source of IL-21 ([@b21-ol-0-0-11822]); within this population, T follicular helper cells and Th17 cells have been found to produce the highest amounts of IL-21, whereas the production from NK cells was observed to be slightly lower ([@b21-ol-0-0-11822]). However, IL-21 has been revealed to be an important regulator of the differentiation, proliferation, survival and activation of NK cells ([@b22-ol-0-0-11822]--[@b24-ol-0-0-11822]). IL-21 reportedly serves multiple functions, such as lymphocytes proliferation, cytotoxicity of CD8+ T cells and natural killer (NK) cells, B-cell differentiation and Th17 development, in multiple lymphoid organs and myeloid populations, in addition to within epithelial cells ([@b25-ol-0-0-11822]). Recently, the therapeutic efficacy of IL-21 as single-agent immunotherapy has been tested in phase I and II clinical trials to treat different types of cancers including melanoma, renal cell carcinoma and metastatic colorectal cancer ([@b13-ol-0-0-11822]). A modest clinical outcome was observed when patients with stage IV malignant melanoma who did not receive prior treatment were treated with IL-21 at a dose of 30 mg/kg/d in 5-day cycles. The overall response rate of this study according to RECIST was about 8%, with one of 14 patients achieving a complete response and one patient having a confirmed partial response ([@b26-ol-0-0-11822]). Current research is focusing on the potential of IL-21 in combination with targeted therapy. Such as cetuximab, an antibody of epidermal growth factor receptor (EGFR) ([@b27-ol-0-0-11822]). In a phase I trial, the combination of IL-21 and cetuximab achieved the best response in 60% of patients with stage IV colorectal cancer ([@b28-ol-0-0-11822]). However, IL-21 appears to have a major role in promoting the inflammation-induced development of colon cancer, thus the aforementioned clinical trial was terminated ([@b28-ol-0-0-11822]).

In the present study, IL-21 expression levels were detected in the OSCC tissues and the results revealed that IL-21 expression levels were significantly decreased in OSCC tissues, which was closely associated with the clinical stage of the tumor and lymph node metastasis. These findings suggested that the expression of IL-21 may be defective during tumor progression. Consistent with these results, Dutta *et al* ([@b29-ol-0-0-11822]) also reported that the levels of IL-21 mRNA transcripts decreased in OSCC tissues and a similar trend of transcript expression of IL-21 was also observed in peripheral blood of patients with OSCC. Subsequently, the role of IL-21 on the proliferation, migration and apoptosis of OSCC cells was investigated *in vitro*. IL-21 overexpression was revealed to inhibit cell proliferation and migration, whilst promoting cell apoptosis in CAL-27 cells. Another study on laryngeal cancer cells also demonstrated that when IL-21 was overexpressed in Hep-2 cells, the proliferation and invasion of Hep-2 cells decreased ([@b30-ol-0-0-11822]). In hepatocellular carcinoma (HCC), exogenous IL-21 may reinvigorate NK cells in patients with HBV-associated HCC, resulting in significantly increased levels of cytotoxicity, degranulation and cytokine expression, and the reinvigoration of NK function by IL-21 is mediated by the STAT1 signaling pathway ([@b31-ol-0-0-11822]). In various solid and hematological tumors, IL-21 improves effector T cell and NK cell cytotoxic activity and IL-21 was also discovered to inhibit cancer cell viability by stimulating interferon-γ production and by increasing the granularity of NK cells ([@b32-ol-0-0-11822],[@b33-ol-0-0-11822]). Therefore, IL-21 may be an effective agent for cancer immunotherapy ([@b34-ol-0-0-11822]).

In conclusion, the present study indicated that IL-21 may exert a potent inhibitory effect over OSCC growth *in vitro*. Future studies should aim to investigate the role of IL-21 in OSCC animal models in order to determine its potential as an immunotherapeutic target for OSCC.
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![Expression levels of IL-21 in OSCC tissues. (A) mRNA expression levels of IL-21 in OSCC tissues and adjacent normal tissues were detected using reverse transcription-quantitative PCR. (B) Protein expression levels of IL-21 in OSCC tissues and adjacent normal tissues were detected using western blotting. (C) Semi-quantification of the western blotting data presented in part B. Expression levels of IL-21 were normalized to β-actin. The data are presented as the mean ± SEM from three independent experiments. \*\*P\<0.01 vs. the normal tissues. (D) Representative immunohistochemistry images of IL-21 expression levels in OSCC tissues and adjacent normal tissues. Magnification, ×100 or ×400. IL-21, interleukin-21; OSCC, oral squamous cell carcinoma; N, Normal tissues; C, cancer tissues.](ol-20-03-3006-g00){#f1-ol-0-0-11822}

![Adenoviral-mediated overexpression of IL-21 in CAL-27 cells. (A) Reverse transcription-quantitative PCR or (B) western blotting was used to analyze the mRNA or protein expression levels, respectively, of IL-21 in CAL-27 cells infected with Ad-null or Ad-IL-21. (C) Semi-quantification of the western blotting data presented in part B. Expression levels of IL-21 were normalized to β-actin. The data were expressed as the mean ± SEM from three independent experiments. \*P\<0.05 vs. the control group; ^\#^P\<0.05 vs. the Ad-null group. IL-21, interleukin-21; Ad, adenovirus.](ol-20-03-3006-g01){#f2-ol-0-0-11822}

![IL-21 inhibits the proliferation and migration of CAL-27 cells. (A) Cell viability was measured using a Cell Counting Kit-8 assay in CAL-27 cells infected with Ad-null or Ad-IL-21. The value of the control group was set to 100% and the values of the other groups were normalized to the control group. (B) Cell migration was assessed using a wound healing assay in CAL-27 cells infected with Ad-null or Ad-IL-21. Magnification, ×400. (C) Semi-quantification of the cell migration rate (%) from part B. Data are expressed as the mean ± SEM from three independent experiments. \*P\<0.05 vs. the control group; ^\#^P\<0.05 vs. the Ad-null group. Il-21, interleukin-21; Ad, adenovirus.](ol-20-03-3006-g02){#f3-ol-0-0-11822}

![IL-21 induces the apoptosis of CAL-27 cells. (A) CAL-27 cells were infected with Ad-null or Ad-IL-21 and TUNEL staining was performed. Scale bar, 50 µm. (B) Percentage of TUNEL-positive cells was semi-quantified to determine the percentage rate of apoptosis. (C) Western blotting was used to analyze the expression levels of the pro-apoptotic proteins, c-caspase-3 and Bax, and the anti-apoptotic protein, Bcl-2 in CAL-27 cells infected with Ad-null or Ad-IL-21. (D) Semi-quantification of the expression levels of c-caspase-3 and the Bax/Bcl-2 ratio from part C. Expression levels were normalized to β-actin. The data are presented as the mean ± SEM from three independent experiments. \*P\<0.05 vs. the control group; ^\#^P\<0.05 vs. the Ad-null group. IL-21, interleukin-21; Ad, adenovirus; c-, cleaved.](ol-20-03-3006-g03){#f4-ol-0-0-11822}

![IL-21 can induce the apoptosis of CAL-27 cells. (A) CAL-27 cells were infected with Ad-null or Ad-IL-21 and flow cytometry was performed. (B) Semi-quantification of the apoptotic data from part A. The data are presented as the mean ± SEM from three independent experiments. \*P\<0.05 vs. the control group; ^\#^P\<0.05 vs. the Ad-null group. IL-21, interleukin-21; Ad, adenovirus; APC, allophycocyanin; ADD, 7′-aminoactinomycin D.](ol-20-03-3006-g04){#f5-ol-0-0-11822}

![IL-21 inhibits the activation of the JNK signaling pathway. (A) Western blotting was used to analyze the expression levels of JNK and p-JNK in CAL-27 cells infected with Ad-null or Ad-IL-21. (B) Semi-quantification of the expression levels of p-JNK/JNK from part A. Expression levels were normalized to β-actin. (C) Western blotting was used to analyze the expression levels of AKT and p-AKT in CAL-27 cells infected with Ad-null or Ad-IL-21. (D) Semi-quantification of the expression levels of p-AKT/AKT from part C. Expression levels were normalized to β-actin. The data are expressed as the mean ± SEM from three independent experiments. \*P\<0.05 vs. the control group; ^\#^P\<0.05 vs. the Ad-null group. IL-21, interleukin-21; Ad, adenovirus; p-, phosphorylated.](ol-20-03-3006-g05){#f6-ol-0-0-11822}

###### 

Association between interleukin-21 expression and the clinical and histopathological features of patients with oral squamous cell carcinoma (n=45).

  Variables               Total number of patients, n   Positive   Positive rate (%)   χ^2^    P-value
  ----------------------- ----------------------------- ---------- ------------------- ------- -----------------------------------------------------
  Sex                                                                                          
    Male                  29                            17         58.62               0.024   0.878
    Female                16                            9          56.25                       
  Age, years                                                                                   
    ≥60                   24                            14         58.33               0.007   0.936
    \<60                  21                            12         57.14                       
  Tumor size, cm                                                                               
    ≥3                    24                            13         54.17               0.275   0.600
    \<3                   21                            13         61.90                       
  TNM stage                                                                                    
    I or II               14                            13         92.85               8.270   0.004^[b](#tfn2-ol-0-0-11822){ref-type="table-fn"}^
    III or IV             31                            13         41.94                       
  Differentiation                                                                              
    Well                  13                            11         84.62               3.961   0.047^[a](#tfn1-ol-0-0-11822){ref-type="table-fn"}^
    Moderate/poor         32                            15         46.87                       
  Lymph node metastasis                                                                        
    Negative              12                            11         91.67               5.926   0.015^[a](#tfn1-ol-0-0-11822){ref-type="table-fn"}^
    Positive              33                            15         45.45                       

P\<0.05.

P\<0.01.

[^1]: Contributed equally
